Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleElotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial.AuthorsDimopoulos, Meletios A.; Weisel, Katja; Lonial, Sagar; White, Darrell; Moreau, Philippe; Mateos, Maria-Victoria; San-Miguel, Jesus; Anderson, Kenneth C.; Shpilberg, Ofer; Grosicki, Sebastian; Spicka, Ivan; Walter-Croneck, Adam; Magen, Hila; Belch, Andrew; Reece, Donna; Beksac, Meral; Ganetsky, Alex; Jou, Ying-Ming; McKiver, Mihaela Popa; Singhal, Anil K.PublicationClinical Lymphoma, Myeloma & Leukemia, 2019, Vol 19, pe15ISSN2152-2650Publication typeArticleDOI10.1016/j.clml.2019.09.022